Furthermore, our survival analysis showed that patients with TIGIT alterations had the same exceptionally positive outcomes as those with POLE alterations, indicating that this molecule may warrant further investigation in our NZ panel or provide evidence for anti-TIGIT therapy for the treatment of late-stage POLEmut tumours. This evidence concerns the gene POLE and neoplasm.